<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03521037</url>
  </required_header>
  <id_info>
    <org_study_id>CO-338-078</org_study_id>
    <nct_id>NCT03521037</nct_id>
  </id_info>
  <brief_title>Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor</brief_title>
  <official_title>A Phase 1, Open-Label, Parallel Group Study to Determine the Pharmacokinetics, Safety and Tolerability of Rucaparib in Patients With an Advanced Solid Tumor and Either Moderate Hepatic Impairment or Normal Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clovis Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clovis Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1, open-label, parallel group, PK, safety and tolerability study in patients with an
      advanced solid tumor and either normal hepatic function (Group 1, n = 8) or moderate hepatic
      impairment (Group 2, n = 8) according to the NCI-ODWG criteria. Patients in Group 1 and Group
      2 may be enrolled in parallel, with preferential enrollment of Group 2 patients before Group
      1 patients. The study will consist of 2 parts: a single-dose PK part (Part I) and a
      continuous rucaparib treatment part (Part II).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Part I, eligible patients will receive a single oral dose of 600 mg rucaparib followed by
      intensive plasma PK sampling up to Day 7 (hour 144). In Part II, patients may continue to
      receive continuous oral rucaparib in 28 day cycles. The starting dose for all Group 1
      patients will be 600 mg BID. The first 2 patients with moderate hepatic impairment (Group 2)
      that enter Part II will receive a starting dose of 400 mg BID rucaparib; a lower dose of
      rucaparib may also be set based on PK results observed in Part I. If this initial starting
      dose is determined to be safe and tolerable as determined by real-time PK data and dose
      limiting toxicities (DLT) observed during the first 28 days of rucaparib, the starting dose
      of rucaparib may be increased in subsequent Group 2 patients. The starting dose for Group 2
      patients may also be lowered, based on the patients' real time PK and emerging safety data.
      The Sponsor and key clinical research organization (CRO) staff will review available adverse
      event, laboratory, and PK data to determine the starting dose for subsequent Group 2
      patients, as well as allowing intra-patient dose escalation of rucaparib after Cycle
      1.Treatment with rucaparib will continue until progression of disease, unacceptable toxicity,
      death, loss to follow-up, withdrawal of consent, or other appropriate clinical reason for
      discontinuation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma rucaparib concentration (Cmax)</measure>
    <time_frame>day 1 to day 7</time_frame>
    <description>PK parameter of rucaparib to be calculated from the plasma concentration-time data</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma rucaparib concentration-time curve from time zero up to the last time point with quantifiable concentration (AUC0-last)</measure>
    <time_frame>day 1 to day 7</time_frame>
    <description>PK parameter of rucaparib to be calculated from the plasma concentration-time data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma rucaparib concentration-time curve from time zero up to time infinity (AUC0-inf)</measure>
    <time_frame>day 1 to day 7</time_frame>
    <description>PK parameter of rucaparib to be calculated from the plasma concentration-time data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) of rucaparib</measure>
    <time_frame>day 1 to day 7</time_frame>
    <description>PK parameter of rucaparib to be calculated from the plasma concentration-time data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to attain maximum plasma rucaparib concentration (Tmax)</measure>
    <time_frame>day 1 to day 7</time_frame>
    <description>PK parameter of rucaparib to be calculated from the plasma concentration-time data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance (CL/F) of rucaparib</measure>
    <time_frame>day 1 to day 7</time_frame>
    <description>PK parameter of rucaparib to be calculated from the plasma concentration-time data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution during terminal phase (Vz/F) of rucaparib</measure>
    <time_frame>day 1 to day 7</time_frame>
    <description>PK parameter of rucaparib to be calculated from the plasma concentration-time data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough plasma concentration of rucaparib at steady state (Cmin,ss)</measure>
    <time_frame>approximately 4 months</time_frame>
    <description>PK parameter of rucaparib to be calculated from the plasma concentration-time data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance (CLR) of rucaparib</measure>
    <time_frame>day 1 to day 2</time_frame>
    <description>PK parameter of rucaparib to be calculated from the plasma and urine concentration-time data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative amount of rucaparib excreted in urine during urine collection period post rucaparib dose</measure>
    <time_frame>day 1 to day 2</time_frame>
    <description>PK parameter of rucaparib to be calculated based on urine concentration-time data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of administered rucaparib excreted into urine (Fe/F) during urine collection period post rucaparib dose</measure>
    <time_frame>day 1 to day 2</time_frame>
    <description>PK parameter of rucaparib to be calculated based on the amount of rucaparib recovered in urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events [Safety and Tolerability]</measure>
    <time_frame>From Day 1 to last patient visit in Part II (approximately 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinical laboratory abnormalities [Safety and Tolerability]</measure>
    <time_frame>From Day 1 to last patient visit in Part II (approximately 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of dose modifications [Safety and Tolerability]</measure>
    <time_frame>From Day 1 to last patient visit in Part II (approximately 2 years)</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Maximum plasma metabolite concentration (Cmax)</measure>
    <time_frame>day 1 to day 7</time_frame>
    <description>PK parameter for rucaparib metabolite(s) to be calculated from plasma concentration-time data</description>
  </other_outcome>
  <other_outcome>
    <measure>Area under the plasma metabolite concentration-time curve from time zero up to the last time point with quantifiable concentrations (AUC0-last)</measure>
    <time_frame>day 1 to day 7</time_frame>
    <description>PK parameter for rucaparib metabolite(s) to be calculated from plasma concentration-time data</description>
  </other_outcome>
  <other_outcome>
    <measure>Area under the plasma metabolite concentration-time curve from time zero up to time infinity (AUC0-inf)</measure>
    <time_frame>day 1 to day 7</time_frame>
    <description>PK parameter for rucaparib metabolite(s) to be calculated from plasma concentration-time data</description>
  </other_outcome>
  <other_outcome>
    <measure>Terminal half-life (t1/2) of metabolite</measure>
    <time_frame>day 1 to day 7</time_frame>
    <description>PK parameter for rucaparib metabolite(s) to be calculated from plasma concentration-time data</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to attain maximum plasma metabolite concentration (Tmax)</measure>
    <time_frame>day 1 to day 7</time_frame>
    <description>PK parameter for rucaparib metabolite(s) to be calculated from plasma concentration-time data</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma trough concentration of metabolite(s) at steady state (Cmin,ss)</measure>
    <time_frame>day 1 to day 7</time_frame>
    <description>PK parameter for rucaparib metabolite(s) to be calculated from plasma concentration-time data</description>
  </other_outcome>
  <other_outcome>
    <measure>Renal clearance (CLR) of metabolite(s)</measure>
    <time_frame>day 1 to day 2</time_frame>
    <description>PK parameters for rucaparib metabolite(s) to be calculated from plasma and urine concentration-time data</description>
  </other_outcome>
  <other_outcome>
    <measure>Cumulative amount of rucaparib metabolite(s) excreted in urine during urine collection period post rucaparib dose</measure>
    <time_frame>day 1 to day 2</time_frame>
    <description>PK parameter for rucaparib metabolite(s) to be calculated from urine concentration-time data</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>no name</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1: patients with normal hepatic function Group 2: patients who have moderate hepatic impairment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rucaparib camsylate</intervention_name>
    <description>In Part I, eligible patients will receive a single oral dose of 600 mg rucaparib followed by intensive plasma PK sampling up to Day 7 (hour 144). In Part II, patients may continue to receive continuous oral rucaparib in 28 day cycles.</description>
    <arm_group_label>no name</arm_group_label>
    <other_name>rubraca</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All Patients:

          -  Patients ≥18 years of age at the time the ICF is signed;

          -  Patients with a histologically or cytologically confirmed advanced solid tumor who, in
             the opinion of the Investigator, could potentially benefit from treatment with
             rucaparib

          -  ECOG PS less than or equal to 2

          -  Adequate bone marrow and renal function

        Hepatically Impaired Patients (in addition):

          -  Stable hepatic impairment as judged by the Investigator

          -  Moderate Hepatic Impairment (NCI-ODWG criteria) during Screening

        Patients with Normal Hepatic Function (in addition):

        • Normal Hepatic Function (NCI-ODWG criteria)

        Exclusion Criteria:

        All Patients:

          -  Prior treatment with chemotherapy, radiation, antibody therapy or other immunotherapy,
             gene therapy, vaccine therapy, angiogenesis inhibitors, or investigational drugs
             within 14 days prior to day 1

          -  Ongoing toxicity ≥ Grade 2 per Common Terminology Criteria for Adverse Events criteria
             (CTCAE version 4.03)

          -  Prior treatment with any poly adenosine diphosphate ribose polymerase inhibitor

          -  Arterial or venous thrombi (including cerebrovascular accident), myocardial
             infarction, admission for unstable angina, cardiac angioplasty, stenting or poorly
             controlled hypertension within the last 3 months prior to Screening

          -  Pre-existing duodenal stent, and/or any gastrointestinal disorder or defect that
             would, in the opinion of the Investigator, interfere with absorption of rucaparib

          -  Hospitalization for bowel obstruction within 3 months prior to Day 1

          -  Untreated or symptomatic central nervous system (CNS) metastases

          -  Evidence or history of bleeding disorder

          -  Acute illness within 14 days prior to Day 1

          -  Active second malignancy

        Hepatically Impaired Patients (in addition):

          -  Severe hepatic encephalopathy (Grade &gt;2);

          -  History of liver transplantation;

          -  Advanced ascites or ascites that require drainage and albumin supplementation, as
             judged by the Investigator;

          -  Acute damage of the liver with Grade 4 AST/ALT values
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clovis Oncology Clinical Trial Information (USA)</last_name>
    <phone>1-855-262-3040</phone>
    <email>clovistrials@emergingmed.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clovis Oncology Clinical Trial Information (ex-US)</last_name>
    <phone>1-303-625-5160</phone>
    <email>clovistrials@emergingmed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Onkologicka klinika VFN a 1. LF UK</name>
      <address>
        <city>Praha</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milada Zemanova</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pharmaceutical Research Associates CZ</name>
      <address>
        <city>Praha</city>
        <zip>170 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milada Zemanova</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalistyczny w Białej Podlaskiej</name>
      <address>
        <city>Biała Podlaska</city>
        <zip>21-500</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Centkowski</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Med Polonia Sp. z o.o.</name>
      <address>
        <city>Poznań</city>
        <zip>60-693</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodryg Ramlau</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zachodniopomorskie Centrum Onkologii w Szczecinie</name>
      <address>
        <city>Szczecin</city>
        <zip>71-730</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorota Nowak</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>BioVirtus Centrum Medyczne</name>
      <address>
        <city>Warszawa</city>
        <zip>02-681</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Tomaszewska-Kiecana, MD</last_name>
      <phone>48 22 545.84.64</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Summit Clinical Research s.r.o.</name>
      <address>
        <city>Bratislava</city>
        <zip>831 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miriam Drahokoupilova</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northern Centre for Cancer Care</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yvette Drew</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2018</study_first_submitted>
  <study_first_submitted_qc>May 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2018</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rucaparib</keyword>
  <keyword>CO-338</keyword>
  <keyword>Clovis</keyword>
  <keyword>Clovis Oncology</keyword>
  <keyword>PARP inhibitor</keyword>
  <keyword>hepatic impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rucaparib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

